These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 34187859)

  • 21. A Parkinson's disease patient displaying increased neuromelanin-sensitive areas in the substantia nigra after rehabilitation with tDCS: a case report.
    Ishikuro K; Hattori N; Imanishi R; Furuya K; Nakata T; Dougu N; Yamamoto M; Konishi H; Nukui T; Hayashi T; Anada R; Matsuda N; Hirosawa H; Tanaka R; Shibata T; Mori K; Noguchi K; Kuroda S; Nakatsuji Y; Nishijo H
    Neurocase; 2021 Oct; 27(5):407-414. PubMed ID: 34503372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Azevedo P; Ferreira J; Abreu D; Gonçalves N; Nunes RG; Campos J; Ferreira JJ
    Mov Disord; 2015 Jun; 30(7):953-9. PubMed ID: 25758364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing neuromelanin contrast in the substantia nigra and locus coeruleus using a magnetization transfer contrast prepared 3D gradient recalled echo sequence.
    Liu Y; Li J; He N; Chen Y; Jin Z; Yan F; Haacke EM
    Neuroimage; 2020 Sep; 218():116935. PubMed ID: 32413460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease related signal change in the nigrosomes 1-5 and the substantia nigra using T2* weighted 7T MRI.
    Schwarz ST; Mougin O; Xing Y; Blazejewska A; Bajaj N; Auer DP; Gowland P
    Neuroimage Clin; 2018; 19():683-689. PubMed ID: 29872633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease.
    Castellanos G; Fernández-Seara MA; Lorenzo-Betancor O; Ortega-Cubero S; Puigvert M; Uranga J; Vidorreta M; Irigoyen J; Lorenzo E; Muñoz-Barrutia A; Ortiz-de-Solorzano C; Pastor P; Pastor MA
    Mov Disord; 2015 Jun; 30(7):945-52. PubMed ID: 25772492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease.
    Reimão S; Pita Lobo P; Neutel D; Guedes LC; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    J Parkinsons Dis; 2015; 5(3):561-7. PubMed ID: 26406136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vivo Assessment of Brainstem Depigmentation in Parkinson Disease: Potential as a Severity Marker for Multicenter Studies.
    Schwarz ST; Xing Y; Tomar P; Bajaj N; Auer DP
    Radiology; 2017 Jun; 283(3):789-798. PubMed ID: 27820685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson's disease.
    Prasad S; Stezin A; Lenka A; George L; Saini J; Yadav R; Pal PK
    Eur J Neurol; 2018 Apr; 25(4):680-686. PubMed ID: 29341412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the Role of Locus Coeruleus Degeneration in Essential Tremor and Parkinson's Disease with Sleep Disorders.
    Liu S; Zhou C; Fang Y; Zhu B; Wu H; Wu C; Guo T; Wu J; Wen J; Qin J; Chen J; Duanmu X; Tan S; Guan X; Xu X; Zhang M; Zhang B; Zhao G; Yan Y
    J Parkinsons Dis; 2024; 14(4):833-842. PubMed ID: 38728202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-echo-time magnitude image derived from quantitative susceptibility mapping could resemble neuromelanin-sensitive MRI image in substantia nigra.
    Liu XL; Yang LQ; Liu FT; Wu PY; Zhang Y; Zhuang H; Shi YH; Wang J; Geng DY; Li YX
    BMC Neurol; 2020 Jun; 20(1):262. PubMed ID: 32605601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Denoising approach with deep learning-based reconstruction for neuromelanin-sensitive MRI: image quality and diagnostic performance.
    Oshima S; Fushimi Y; Miyake KK; Nakajima S; Sakata A; Okuchi S; Hinoda T; Otani S; Numamoto H; Fujimoto K; Shima A; Nambu M; Sawamoto N; Takahashi R; Ueno K; Saga T; Nakamoto Y
    Jpn J Radiol; 2023 Nov; 41(11):1216-1225. PubMed ID: 37256470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited.
    Langley J; Huddleston DE; Merritt M; Chen X; McMurray R; Silver M; Factor SA; Hu X
    Hum Brain Mapp; 2016 Jul; 37(7):2547-56. PubMed ID: 27029026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network.
    Gaurav R; Valabrègue R; Yahia-Chérif L; Mangone G; Narayanan S; Arnulf I; Vidailhet M; Corvol JC; Lehéricy S
    Neuroimage Clin; 2022; 36():103250. PubMed ID: 36451356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantifying iron deposition within the substantia nigra of Parkinson's disease by quantitative susceptibility mapping.
    An H; Zeng X; Niu T; Li G; Yang J; Zheng L; Zhou W; Liu H; Zhang M; Huang D; Li J
    J Neurol Sci; 2018 Mar; 386():46-52. PubMed ID: 29406966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI index of glymphatic system mediates the influence of locus coeruleus on cognition in Parkinson's disease.
    Wang X; Huang P; Haacke EM; Wu P; Zhang X; Zhang H; Cheng Z; Tang R; Liu F; Liu Y; Shi X; Liu P; Zhang Y; Jin Z; Chen S; He N; Yan F
    Parkinsonism Relat Disord; 2024 Jun; 123():106558. PubMed ID: 38518543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases.
    Zarow C; Lyness SA; Mortimer JA; Chui HC
    Arch Neurol; 2003 Mar; 60(3):337-41. PubMed ID: 12633144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Motor asymmetry and neuromelanin imaging: Concordance in Parkinson's disease.
    Prasad S; Saini J; Yadav R; Pal PK
    Parkinsonism Relat Disord; 2018 Aug; 53():28-32. PubMed ID: 29709506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.